Therapygenetics in mindfulness-based cognitive therapy: Do genes have an impact on therapy-induced change in real-life positive affective experiences

Translational Psychiatry

Volumn 4, Issue , 2014, Pages

  Bakker, J M ^a   Lieverse, R ^a   Menne Lothmann, C ^a   Viechtbauer, W ^a   Pishva, E ^a   Kenis, G ^a   Geschwind, N ^b   Peeters, F ^a   Van Os, J ^a,c   Wichers, M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Department of Clinical Psychological Science ^*  (Netherlands)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE 4 RECEPTOR; MU OPIATE RECEPTOR; MUSCARINIC M2 RECEPTOR;

ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; DEPRESSION; GENETIC VARIABILITY; GENOTYPE; HAMILTON SCALE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MINDFULNESS BASED COGNITIVE THERAPY; PERSONALIZED MEDICINE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; AFFECT; ANXIETY DISORDER; GENE FUNCTION; GENETIC DIFFERENCE; HAMILTON DEPRESSION RATING SCALE; POSITIVE AFFECT; PROSPECTIVE STUDY; SEMI STRUCTURED INTERVIEW; TREATMENT DURATION; TREATMENT RESPONSE; GENETICS; HUMAN ACTIVITIES; INDIVIDUALITY; MINDFULNESS; PHYSIOLOGY; PROCEDURES; PSYCHOLOGY;

AFFECT; COGNITIVE THERAPY; DEPRESSION; HUMAN ACTIVITIES; HUMANS; INDIVIDUALITY; MINDFULNESS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 84898604307     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.23     Document Type: Article

References (91)

1. Forbes EE, Dahl RE. Neural systems of positive affect: relevance to understanding child and adolescent depression?. Dev Psychopathol 2005; 2005: 3.
2. Geschwind N, Peeters F, Jacobs N, Delespaul P, Derom C, Thiery E et al. Meeting risk with resilience: high daily life reward experience preserves mental health. Acta Psychiatr Scand 2010; 122: 129-138.
3. Wichers M, Peeters F, Geschwind N, Jacobs N, Simons CJP, Derom C et al. Unveiling patterns of affective responses in daily life may improve outcome prediction in depression: a momentary assessment study. J Affect Disord 2010; 124: 191-195.
4. Wichers MC, Myin-Germeys I, Jacobs N, Peeters F, Kenis G, Derom C et al. Evidence that moment-to-moment variation in positive emotions buffer genetic risk for depression: a momentary assessment twin study. Acta Psychiatr Scand 2007; 115: 451-457.
5. Fredrickson BL, Levenson RW. Positive emotions speed recovery from the cardiovascular sequalae of negative emotions. Cogn Emot 1998; 12: 191-220.
6. Fredrickson BL, Mancuso RA, Branigan C, Tugade MM. The undoing effect of positive emotions. Motiv Emot 2000; 24: 237-258.
7. Tugade MM, Fredrickson BL. Resilient individuals use positive emotions to bounce back from negative emotional experiences. J Pers Soc Psychol 2004; 86: 320-333.
8. Jacobs N, van Os J, Derom C, Thiery E, Delespaul P, Wichers M. Neuroticism explained? From a non-informative vulnerability marker to informative personcontext interactions in the realm of daily life. Br J Clin Psychol 2011; 50: 19-32.
9. Ong AD, Zautra AJ, Carrington Reid M. Psychological resilience predicts decreases in pai catastrophizing through positive emotions. Psychol Aging 2010; 25: 516-523.
10. Zautra AJ, Fasman R, Reich JW, Harakas P, Johnson LM, Olmsted ME et al. Fibromyalgia: evidence for deficits in positive affect regulation. Psychosom Med 2005; 67: 147-155.
11. Fredrickson BL, Cohn MA, Coffey KA, Pek J, Finkel S. Open hearts build lives: positive emotions, induced through loving-kindness meditation, build consequential personal resources. J Pers Soc Psychol 2008; 95: 1045-1062.
12. Gayner B, Esplen MJ, DeRoche P, Wong J, Bishop S, Kavanagh L et al. A randomized controlled trial of mindfulness-based stress reduction to manage affective symptoms and improve quality of life in gay men living with HIV. J Behav Med 2012; 35: 272-285.
13. Geschwind N, Peeters F, Drukker M, Van Os J, Wichers M. Mindfulness training increases momentary positive emotions and reward experience in adults vulnerable to depression: a randomized controlled trial. J Consult Clin Psychol 2011; 79: 618-628.
14. Spek AA, van Ham NC, Nyklícek I. Mindfulness-based therapy in adults with an autism spectrum disorder: a randmized controlled trial. Res Dev Disabil 2013; 34: 246-253.
15. Eley TC, Hudson JL, Creswell C, Tropeano M, Lester KJ, Cooper P et al. Therapygenetics: the 5HTTLPR and response to psychological therapy. Mol Psychiatr 2012; 17: 236-237.
16. Beevers CG, McGeary JE. Therapygenetics: moving towards personalized psychotherapy treatment. Trends Cogn Sci 2012; 16: 11-12.
17. Boardman JD, Blalock CL, Button TM. Sex differences in the heritability of resilience. Twin Res Hum Genet 2008; 11: 12-27.
18. Eid M, Riemann R, Angleitner A, Borkenau P. Sociability and positive emotionality: genetic and environmental contributions to the covariation between different facets of extraversion. J Pers 2003; 71: 319-346.
19. Dreher JC, Kohn P, Kolachana B, Weinberger DR, Berman KF. Variation in dopamine genes influence responsivity of the human reward system. Proc Natl Acad Sci USA 2009; 106: 617-622.
20. Wichers M, Aguilera M, Kenis G, Krabbendam L, Myin-Germeys I, Jacobs N et al. The catechol-O-methyl transferase Val158Met polymorphism and experience of reward in the flow of daily life. Neuropsychopharmacology 2008; 33: 3030-3036.
21. Costa e Silva JA. Personalized medicine in psychiatry: new technologies and approaches. Metabolism 2013; 62: 25.
22. Arias-Carrión O, Stamelou M, Murillo-Rodríguez E, Menéndez-González M, Pöppel E. Dopaminergic reward system: a short integrative review. Int Arch Med 2010; 3: 24-29.
23. Haber SN, Knutson B. The reward circuit: Linking primate anatomy and human imaging. Neuropsychopharmacology 2010; 35: 4-26.
24. Kelly AE, Berridge KC. The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 2002; 22: 3306-3311.
25. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007; 64: 327-337.
26. Di Chiara G, North RA. Neurobiology of opiate abuse. Trends Pharmacol Sci 1992; 13: 185-193.
27. Van Ree JM, Gerrits MAFM, Vanderschuren LJMJ. Opioids, reward and addicition: an encounter of biology, psychology and medicine. Pharmacol Rev 1999; 5: 341-396.
28. van Ree JM, Niesink RJM, Van Wolfswinkel LV, Ramsey NF, Kornet MLMW, van Furth WR et al. Endogenous opioids and reward. Eur J Pharacol 2000; 405: 89-101.
29. Dilts RP, Kalivas PW. Autoradiographic localization of mu-opioid and neurotensin receptors within the mesolimbic dopamine system. Brain Res 1989; 488: 311-327.
30. Dilts RP, Kalivas PW. Autodiographic localization of delta opioid receptors within the mesocorticolimbic dopamine system using radioioidinated [2-D-penicillamine, 5-D-penicillamine] enkephalin (125I-DPDPE). Synapse 1990; 6: 121-132.
31. Lester KJ, Eley TC. Therapygenetics: using genetic markers to predict response to psychological treatment for mood and anxiety disorders. Biol Mood Anxiety Disord 2013; 3: 2045-5380.
32. Moffit TE, Caspi A, Rutter M. Measured gene-environment interactions in psychopathology: concepts, research strategies, and implications for research, intervention, and public understanding of genetics. Persp Psychol Sci 2006; 1: 5-27.
33. Bogdan R, Nikolova YS, Pizzagalli DA. Neurogenetics of depression: a focus on reward processing and stress sensitivity. Neurobiol Disord 2013; 52: 12-23.
34. Hasler G, Drevets WC, Manji HK, Charney DS. Discovering endophenotypes for major depression. Neuropsychopharmacology 2004; 29: 1765-1781.
35. Delespaul PAEG. Assessing Schizophrenia in Daily Life: the Experience Sampling Method. Maastricht University Press: Maastricht, The Netherlands, 2005.
36. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr 1960; 23: 56-62.
37. First MB, Spitzer RL, Gibbon M, Willims JBW. Structured Clinical Interview for DSMIV-TR Axis 1 Disorders, Research Version. Biometrics Research, New York State Psychiatric Institute: New York, NY, USA 2002.
38. Segal ZV, Williams JMG, Teasdale JD. Mindfulness-based Cognitive Therapy for Depression: a new Approach to Preventing Relapse. Guilford Press: New York, NY, USA, 2002.
39. Teasdale JD, Williams DR. How does cognitive therapy prevent depressive relapse and why should attentional control (mindfulness) training help? Behav Res Ther 1995; 33: 25-39.
40. Csikszentmihalyi M, Larson R. Validity and reliability of the experience sapling method. J Nerv Ment Dis 1987; 175: 526-536.
41. Wichers M, Peeters F, Rutten BP, Jacobs N, Derom C, Thiery E et al. A time-lagged momentary assessment study on daily life physical activity and affect. Health Psychol 2012; 31: 135-144.
42. Myin-Germeys I, van Os J, Schwartz JE, Stone AA, Delespaul PA. EMotional reactivity to daily life stress in psychosis. Arch Gen Psychiatr 2001; 58: 1137-1144.
43. Bagby RM, Ryder AG, Schuller DR, Marshall MB. The Hamilton Depression Rating Scale: has the gold standard become lead weight? Am J Psychiatr 2004; 161: 2163-2177.
44. StataCorp. Stata Statistical Software: Release 12. StataCorp LP: College Station, TX, 2011.
45. Ben Zion IZ, Tessler R, Cohen L, Lerer E, Raz Y, Bachner-Melman R et al. Polymorphisms in the dopamine D4 receptor gene (DRD4) contribute to individual differeneces in human sexual behavior: desire, arousal and sexual function. Mol Psychiatry 2006; 11: 782-786.
46. Licinio J, Dong C, Wong M-L. Novel sequenc variations in the Brain-Derived Neurotrophic Factor gene and association with major depression and antidepresant treatment response. Arch Gen Psychiatry 2009; 66: 488-497.
47. Wang JC, Hinrichs AL, Stock H, Budde J, Allen R, Bertelsen S et al. Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Hum Mol Genet 2004; 13: 1903-1911.
48. Kraschewski A, Reese J, Anghelescu I, Winterer G, Schmidt LG, Gallinat J et al. Association of the dopamine D2 receptor gene with alcohol dependence: haplotypes and subgroups of alcoholics as key factors for understanding receptor function. Pharmacogenet Genomics 2009; 19: 513-527.
49. Balciuniene J, Emilsson L, Oreland L, Pettersson U, Jazin EE. Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Hum Genet 2002; 110: 1-7.
50. Zhang H, Luo X, Kranzler HR, Lappalainen J, Yang B-Z, Krupitsky E et al. Association between two μ-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Human Mol Genet 2006; 15: 807-819.
51. Shabalina S, Zaykin DV, Gris P, Ogurtsov AY, Gauthier J, Shibata K et al. Expansion of the human μ-opioid receptor gene architecture: Novel functional variants. Hum Mol Genet 2008; 18: 1037-1051.
52. Azzato EM, Morton LM, Bergen AW, Wang SS, Chatterjee N, Kvale P et al. SLC6A3 and body mass index in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. BMC Med Genet 2009; 10: 9-17.
53. Diatschenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005; 14: 135-143.
54. Snijders T, Bosker R. Multilevel Analysis: an Introduction to Basis and Advanced Multilevel Modeling. Sage: London, UK, 1999.
55. Faes C, Molenberghs G, Aerts M, Verbeke G. The effective sample size and an alternative small-sample degrees-of-freedom method. Am Stat 2009; 63: 389-399.
56. Snijders TAB, Bosker RJ. Design effects in two-stage samples. Multilevel Analysis: an Introduction to Basic and Advanced Multilevel Modeling. Sage Publishers: London, 1999, pp 22-24.
57. Clayton D Hill M. Wald tests. In: Clayton, D, Hill, M (eds). Statistical Models in Epidemiology. Oxford Science: Oxford, England, 1993, pp 101-102.
58. Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. Am J Public Health 1996; 86: 726-728.
59. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6: 65-70.
60. Belsky J, Bakermans-Kranenburg MJ, van IJzendoorn MH. For better and for worse: differential susceptibility to environmental influences. Curr Direct Psychol Sci 2007; 16: 300-304.
61. Troisi A, Frazzetto G, Carola V, Di Lorenzo G, Coviello M, Siracusano A et al. Variation in the μ-opioid receptor gene (OPRM1) moderates the influence of early maternal care on fearful attachment. Soc Cogn Affect Neurosci 2012; 7: 542-547.
62. Wise RA. The dopamine synapse and the notion of 'pleasure centers' in the brain. Trends Neurosci 1980; 3: 91-95.
63. Berridge K. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology 2007; 191: 391-431.
64. Berridge KC. Food reward: brain substrates of wanting and liking. Neurosci Biobehav Rev 1996; 20: 1-25.
65. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Rev 1998; 28: 309-369.
66. Wise RA. Dual roles of dopamine in food and drug seeking: the drive-reward paradox. Biol Psychiatry 2013; 73: 819-826.
67. Peciña S. Opioid reward 'liking' and 'wanting' in the nucleus accumbens. Physiol Behav 2008; 94: 675-680.
68. Cordeira JW, Frank L, Sena-Esteves M, Pothos EN, Rios M. Brain-derived neurotrophic factor regulates hedonic feeding by acting on the mesolimbic dopamine system. J Neurosci 2010; 30: 2533-2541.
69. Berton O, McClung CA, DiLeone RJ, Krishnan V, Renthal W, Russo SJ et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 2006; 31: 864-868.
70. Nestler EJ, Carlezon WA Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006; 59: 1151-1159.
71. Luo X, Kranzler HR, Zuo L, Wang S, Blumberg HP, Gelernter J. CHRM2 gene predisposes to alcohol dependence, drug dependence and affective disorders: results from an extended case-control structured association study. Hum Mol Genet 2005; 14: 2421-2434.
72. Cohen-Woods S, Gaysin D, Craddock N, Farmer A, Gray J, Gunasinghe Cet al. Depression Case Control (DeCC) Study fails to support involvement of the muscarinic acetylcholine receptor M2 (CHRM2) gene in recurrent major depressive disorder. Hum Mol Genet 2009; 18: 1504-1509.
73. Jung MH, Park BL, Lee B-C, Ro Y, Park R, Shin HD et al. Association of CHRM2 polymorphisms with severity of alcohol dependence. Genes Brain Behav 2011; 10: 256-256.
74. Gibbons AS, Scarr E, McLean C, Sundram S, Dean B. Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J Affect Disord 2009; 116: 184-191.
75. Lai JH, Zhu YS, Huo ZH, Sun RF, Yu B, Wang YP et al. Association study of polymorphisms in the promoter region of DRD4 with schizophrenia, depression, and heroin addiction. Brain Res 2010; 1359: 227-232.
76. Stice E, Yokum S, Zald D, Dagher A. Dopamine-based reward circuitry responsivity, genetics, and overeating. Curr Top Behav Neurosci 2011; 6: 81-93.
77. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000; 405: 857-865.
78. Lonsdorf T, Ruck C, Bergstrom J, Andersson G, Ohman A, Lindefors N et al. The COMTval158met polymorphism is associated with symptom relief during exposure-based cognitive-behavioral treatment in panic disorder. BMC Psychiatry 2010; 10: 99.
79. Reif A, Richter J, Straube B, Hofler M, Lueken U, Gloster AT et al. MAOA and mechanisms of panic disorder revisited: from bench to molecular psychotherapy. Mol Psychiatry 2013; 19: 122-128.
80. Fullana MA, Alonso P, Gratacos M, Jaurrieta N, Jimenez-Murcia S, Segalas C et al. Variation in the BDNF Val66Met polymorphism and response to cognitivebehavior therapy in obsessive-compulsive disorder. Eur Psychiatry 2012; 27: 386-390.
81. Bockting CL, Mocking RJ, Lok A, Koeter MW, Schene AH. Therapygenetics: the 5HTTLPR as a biomarker for response to psychological therapy? Mol Psychiatry 2012; 3: 92.
82. Owen DR, Rupprecht R, Nutt DJ. Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety? J Psychopharmacol 2013; 27: 119-122.
83. Franke L, van Bakel H, Fokkens L, de Jong ED, Egmont-Petersen M, Wijmenga C. Reconstruction of a functional human gene network, with an application for prioritizing positional candidate genes. Am J Hum Genet 2006; 78: 1011-1025.
84. Geschwind N, Nicolson NA, Peeters F, van Os J, Barge-Schaapveld D, Wichers M. Early improvement in positive rather than negative emotion predicts remission from depression after pharmacotherapy. Eur Neuropsychopharmacol 2011; 21: 241-247.
85. Batink T, Peeters F, Geschwind N, van Os J, Wichers M. How does MBCT for depression work? Studying cognitive and affective mediation pathways. PLoS One 2013; 8: e72778.
86. Höhn P, Menne-Lothmann C, Peeters F, Nicolson NA, Jacobs J, Derom Cet al. Moment-to-moment transfer of positive emotions in daily life predicts future course of depression in both general population and patient samples. PLoS One 2013; 8: e75655.
87. Harmon-Jones E, Gable P, Price TF. The influence of affective states varying in motivational intensity on cognitive scope. Front Integr Neurosci 2012; 10: 73.
88. Fredrickson BL. The role of positive emotions in positive psychology. The broaden-and-build theory of positive emotions. Am Psychol 2001; 56: 218-226.
89. Forbes EE, Dahl RE, Almeida JR, Ferrell RE, Nimgaonkar VL, Mansour H et al. PER2 rs2304672 polymorphism moderates circadian-relevant reward circuitry activity in adolescents. Biol Psychiatry 2012; 7: 451-457.
90. Villafuerte S, Heitzeg MM, Foley S, Yau WY, Majczenko K, Zubieta JK et al. Impulsiveness and insula activation during reward anticipation are associated with genetic variants in GABRA2 in a family sample enriched for alcoholism. Mol Psychiatry 2012; 17: 511-519.
91. Grigorenko EL. Epistasis and the genetics of complex traits. In: Plomin R, DeFries J, Craig IW, McGuffin P (eds). Behavioural Genetics in the Postgenomic Era. American Psychological Association: Washington, DC, USA, 2003, pp 247-266.